Detalhe da pesquisa
1.
Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia.
N Engl J Med;
388(4): 319-332, 2023 01 26.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36511784
2.
Plain language summary of zanubrutinib or ibrutinib in chronic lymphocytic leukemia that is resistant to treatment or has come back after treatment.
Future Oncol;
20(12): 717-726, 2024 Apr.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38088119
3.
Zanubrutinib monotherapy for patients with treatment naïve chronic lymphocytic leukemia and 17p deletion.
Haematologica;
106(9): 2354-2363, 2020 10 13.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33054121
4.
Zanubrutinib Versus Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: Interim Analysis of a Randomized Phase III Trial.
J Clin Oncol;
41(5): 1035-1045, 2023 02 10.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36395435
5.
Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia.
J Clin Oncol;
28(10): 1756-65, 2010 Apr 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-20194844
6.
Written advice can provide a safe and acceptable alternative to new patient assessment for selected referrals to haematologists.
Med J Aust;
188(1): 9-12, 2008 Jan 07.
Artigo
em Inglês
| MEDLINE
| ID: mdl-18205554
7.
Fibrinogen Hillsborough: a novel gammaGly309Asp dysfibrinogen with impaired clotting.
Blood;
99(10): 3597-601, 2002 May 15.
Artigo
em Inglês
| MEDLINE
| ID: mdl-11986213